New phase 3 data show Vera Therapeutics’ Trutakna successfully stabilizes kidney function in IgA nephropathy patients, mirroring an earlier clinical success from Otsuka’s Voyxact and heating up competition in a rapidly evolving market race.
Cellares is partnering with Taiwanese biotech GenomeFrontier Therapeutics to evaluate the integrated contract developer and manufacturer’s cell shuttle platform for use in the production of virus-free CAR-T therapies.
Trialynx takes home the DPHARM Idol Disrupt award from the 2026 DPHARM conference.
As Amgen advances its bid to join the first wave of biosimilars to Bristol Myer Squibb and Ono’s oncology megablockbuster Opdivo, the originator drug’s partners are not taking the challenge lying down.
Legend Biotech has found its permanent CEO, poaching 15-year Novartis veteran Ingrid Zhang as the CAR-T specialist eyes its next phase of growth.
The health and hygiene conglomerate, known for brands like Lysol and Mucinex, will spend the funds building out an R&D hub at its new headquarters and finalizing the largest of its seven manufacturing sites by 50%.
As a key player in the automated cell therapy manufacturing space grapples with a recent setback, another is making waves with a major commercial pact.
Following a steady stream of acquisitions that culminated in three biotech buyouts earlier this year, Gilead has now reached “critical mass” in its efforts to diversify into oncology and inflammation, CEO Daniel O’Day told Fierce.
The Fierce Pharma Marketing Awards celebrated winners across 20 different categories, with GSK, Novartis, argenx and more taking home trophies.
The rare disease biotech announced that it would discontinue efforts to develop Voxzogo for children with Noonan syndrome, a genetic growth disorder that can affect height, facial features and the heart.
In a deal that allows Sanofi to shed assets wrapped up in mature products, German drugmaker Cheplapharm will take over 20 medicines and three manufacturing sites from Sanofi. In exchange, Sanofi is picking up a 26.4% stake in the company.
Lindsey Vonn knows more than most about pain. Spending years training as an elite alpine ski racer puts enough pressure on your body, but Vonn’s injuries and her major crash earlier this year that nearly saw her lose her leg put her at a different level.
AbbVie has partnered with the PGA Tour and the 2026 Presidents Cup, teeing up the “Birdies for Brain Health” initiative to funnel cash to six patient advocacy organizations.
The FDA has approved the industry’s first radioligand equivalent in Curium’s lutetium Lu 177 dotatate injection, Bexlutry, after a court cleared the Boston company of all patent claims brought by Novartis.
Shionogi is stepping up promotion of COVID-19 drug Xocova, working with The Bloc on an omnichannel campaign designed to encourage people to contact their healthcare professional after being exposed to the virus.
Healthcare marketing and comms agency, Deerfield Group, is creating a new model for growth while making a series of appointments and promotions to help bolster its plans.
As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously studied in the real world.
The injectable monoclonal antibody is the first to treat muscle atrophy in patients with SMA, according to the FDA.
GSK is consolidating two of its influenza vaccine manufacturing sites into one, leaving hundreds of jobs at risk.
Commercial plans can no longer be static. Acumetis' Swathi Rangan explains how teams can adapt strategy as markets evolve.